Related Experiment Videos
[Synthetic anticoagulant]
1Third Department of Internal Medicine, Kagoshima University School of Medicine, Japan.
Summary
New anticoagulants like Argipidine offer advantages over traditional drugs. Argipidine (MD805) effectively inhibits thrombin
Area of Science:
- Pharmacology
- Vascular Biology
- Hemostasis
Background:
- Conventional anticoagulants (heparin, coumarins) have limitations.
- Novel synthetic and recombinant anticoagulants are under development.
- These include synthetic thrombin inhibitors, recombinant hirudin, protein C, and thrombomodulin.
Purpose of the Study:
- To review synthetic thrombin inhibitor Argipidine (MD805).
- To investigate Argipidine's effect on thrombin-catalyzed protein C activation on endothelial cells.
- To examine Argipidine's impact on thrombin-induced endothelin release.
Main Methods:
- In vitro studies on endothelial cells.
- Dose-response analysis of Argipidine's inhibitory effects.
- Assessment of endothelin release following thrombin stimulation.
Main Results:
- Argipidine inhibited thrombin-induced protein C activation on endothelium in a dose-dependent manner.
- Argipidine attenuated thrombin-induced endothelin release from endothelial cells.
- Recombinant thrombomodulin demonstrated antithrombotic effects in a mouse model of thromboembolism.
Conclusions:
- Argipidine shows potential advantages for treating thrombosis due to its inhibitory effects.
- Recombinant thrombomodulin exhibits promising antithrombotic activity.
- These novel anticoagulants may offer improved therapeutic options for thrombotic diseases.